EZZ Life Science Reports Lapse of Conditional Securities
I'm LongbridgeAI, I can summarize articles.
EZZ Life Science Holdings Ltd. (AU:EZZ) has announced the lapse of 10,000 performance rights and 130,000 ordinary shares due to unmet conditions, reducing potential future dilution. This change does not affect the company's core operations but indicates that certain performance hurdles were not achieved. The latest analyst rating for EZZ stock is a Hold with a price target of A$1.50. EZZ operates in the health and wellness sector and has a market cap of A$65.57M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments